Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Mar 1;57(5):456-63.
doi: 10.1016/j.biopsych.2004.11.043.

A Large, Double-Blind, Randomized Clinical Trial of Methylphenidate in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Affiliations
Clinical Trial

A Large, Double-Blind, Randomized Clinical Trial of Methylphenidate in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Thomas Spencer et al. Biol Psychiatry. .

Abstract

Background: The few controlled studies of methylphenidate (MPH) in adults with attention deficit/hyperactivity disorder (ADHD) have reported equivocal results. A previous, pilot study by our group suggested that these results were due to inadequate dosing.

Method: We conducted a randomized, 6-week, placebo-controlled, parallel study of MPH in 146 adult patients with DSM-IV ADHD using standardized instruments for diagnosis, separate assessments of ADHD, depressive and anxiety symptoms, and a robust average oral daily dose of 1.1 mg/kg/day.

Results: We found a marked therapeutic response for the MPH treatment of ADHD symptoms that exceeded the placebo response (76% vs. 19%). Treatment was safe and well tolerated. Response to MPH was independent of socioeconomic status, gender, and lifetime history of psychiatric comorbidity.

Conclusions: These results confirm that robust doses of MPH are effective in the treatment of adult ADHD.

Similar articles

See all similar articles

Cited by 80 articles

See all "Cited by" articles

Publication types

Feedback